Nuveen
BCAX

Nuveen’s Bicara Therapeutics BCAX Stock Holding History

Nuveen’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.89M Buy
97,223
+53,239
+121% +$1.19M ﹤0.01% 2395
2026
Q1 		$875K Buy
43,984
+5,143
+13% +$88.5K ﹤0.01% 2636
2025
Q4 		$654K Sell
38,841
-5,596
-13% -$95.6K ﹤0.01% 2777
2025
Q3 		$702K Hold
44,437
– – ﹤0.01% 2775
2025
Q2 		$413K Buy
44,437
+19,409
+78% +$231K ﹤0.01% 2944
2025
Q1 		$326K Hold
25,028
– – ﹤0.01% 3016
2024
Q4 		$436K Buy
+25,028
New +$521K ﹤0.01% 3030

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Nuveen's BCAX Position: Q2 2026 in Review

Nuveen increased its Bicara Therapeutics (BCAX) stake by 121% in Q2 2026, buying an estimated $1.19M and bringing the position to 97,223 shares worth $2.89M. The position accounts for ﹤0.01% of the portfolio, ranked #2395.

Nuveen first reported a position in BCAX in Q4 2024 and has held it in 7 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Nuveen held 97,223 shares of Bicara Therapeutics worth $2.89M as of Q2 2026.
  • Nuveen bought 53,239 Bicara Therapeutics shares in Q2 2026, an estimated $1.19M.
  • Bicara Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2395 holding.
  • Nuveen first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.